Mela Sciences (NSDQ:MELA) added five new members to its board of directors this month, looking to tap their expertise in advance of a planned launch in the U.S. and Germany in the first quarter of 2012.

The Irvington, N.Y.-based company named the new directors on the heels of two regulatory wins granting its flagship skin cancer detection device MelaFind market access in the U.S. and Europe.